Responses
Clinical/translational cancer immunotherapy
Original research
Releasing the brakes of tumor immunity with anti-PD-L1 and pushing its accelerator with L19–IL2 cures poorly immunogenic tumors when combined with radiotherapy
Compose a Response to This Article
Other responses
No responses have been published for this article.